Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
Named profile Gilvetmab: Canine PD-1 Immunotherapy and Conditional-Licence ProfileRepresentative category illustration – no product packaging is shown.Gilvetmab: Canine PD-1 Immunotherapy and Conditional-Licence Profile
gilvetmab is covered as caninized anti-pd-1 monoclonal antibody immune-checkpoint inhibitor, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more
Named profile Streptozotocin for Canine Insulinoma: Narrow-Indication Chemotherapy ProfileRepresentative category illustration – no product packaging is shown.Streptozotocin for Canine Insulinoma: Narrow-Indication Chemotherapy Profile
streptozotocin is covered as nitrosourea antineoplastic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read moreNamed profile 5-Fluorouracil in Veterinary Oncology: Critical Feline Toxicity WarningRepresentative category illustration – no product packaging is shown.5-Fluorouracil in Veterinary Oncology: Critical Feline Toxicity Warning
5-fluorouracil (5-FU) is covered as fluoropyrimidine antimetabolites; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read moreNamed profile Vinorelbine in Veterinary Oncology: Lung-Tumour and Marrow-Safety ProfileRepresentative category illustration – no product packaging is shown.Vinorelbine in Veterinary Oncology: Lung-Tumour and Marrow-Safety Profile
vinorelbine is covered as vinca alkaloid antimitotics; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read moreNamed profile Paclitaxel in Veterinary Oncology: Formulation and Regulatory-History ProfileRepresentative category illustration – no product packaging is shown.Paclitaxel in Veterinary Oncology: Formulation and Regulatory-History Profile
paclitaxel is covered as taxane antineoplastic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read moreNamed profile Docetaxel in Veterinary Oncology: Limited-Evidence Taxane ProfileRepresentative category illustration – no product packaging is shown.Docetaxel in Veterinary Oncology: Limited-Evidence Taxane Profile
docetaxel is covered as taxane antineoplastic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more
Named profile Mesna in Veterinary Oncology: Uroprotection With Ifosfamide and CyclophosphamideRepresentative category illustration – no product packaging is shown.Mesna in Veterinary Oncology: Uroprotection With Ifosfamide and Cyclophosphamide
mesna (sodium 2-mercaptoethane sulfonate) is covered as protocol-linked uroprotective medicine; not antitumour therapy, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read moreNamed profile Furosemide as a Cyclophosphamide Uroprotection Adjunct in DogsRepresentative category illustration – no product packaging is shown.Furosemide as a Cyclophosphamide Uroprotection Adjunct in Dogs
furosemide used as a protocol adjunct is covered as loop diuretic used within selected canine cyclophosphamide protocols; not antitumour therapy, with species, evidence, regulatory, safety, interaction and monitoring…
Read more
Named profile H1 and H2 Blockade Around Mast-Cell Degranulation RiskRepresentative category illustration – no product packaging is shown.H1 and H2 Blockade Around Mast-Cell Degranulation Risk
H1-receptor and H2-receptor blocking companion medicines is covered as protocol-linked supportive medicines; not direct antitumour treatment, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led…
Read more
Named profile MOPP and LOPP for Canine Lymphoma: Distinct Alkylator-Rich ProtocolsRepresentative category illustration – no product packaging is shown.MOPP and LOPP for Canine Lymphoma: Distinct Alkylator-Rich Protocols
MOPP and LOPP multi-agent chemotherapy is covered as alkylator-rich canine lymphoma protocols, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read moreNamed profile Vinblastine and Prednisone or Prednisolone for Canine Mast Cell TumoursRepresentative category illustration – no product packaging is shown.Vinblastine and Prednisone or Prednisolone for Canine Mast Cell Tumours
vinblastine with prednisone or prednisolone is covered as combination chemotherapy for selected canine mast-cell tumours, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read moreNamed profile Carboplatin-Based Adjuvant Chemotherapy for Canine OsteosarcomaRepresentative category illustration – no product packaging is shown.Carboplatin-Based Adjuvant Chemotherapy for Canine Osteosarcoma
carboplatin-based adjuvant chemotherapy is covered as platinum chemotherapy after local control of canine appendicular osteosarcoma, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more